Sep 10, 2015

Cartiva Announces First Patient Enrolled in ProxiFuse Post Market Study

Cartiva, Inc., a developer of innovative solutions for the treatment of cartilage damage, osteoarthritis and other musculoskeletal conditions, announced enrollment of the first patient in a prospective, observational study of its FDA-cleared ProxiFuseTM Hammertoe Compression System (“ProxiFuse”). This multicenter post-market study will further demonstrate the safety and effectiveness of ProxiFuse for the fixation of osteotomies and reconstruction of the lesser toes following correction procedures for hammertoe, claw toe and mallet toe. The first study patient was successfully treated by John Maskill, MD of Orthopaedic Associates of Michigan at the Metro Health/OAM Surgery Center in Grand Rapids, Mich.

Hammertoes are permanent and often painful deformities of the second, third or fourth toe that cause the toe to bend at the middle joint instead of pointing forward. Surgical correction of hammer toe deformities is one of the most commonly performed forefoot procedures. One routine procedure is straightening and fusing the joint, in which the ends of the bone are cut and aligned. Pins, screws or other implants are used to keep the toe straight while the bone ends heal together. The innovative ProxiFuse device is designed to provide optimal fixation, compression and stability following the procedure.

“Despite the number of new hammertoe implants that have been introduced in recent years, there is limited clinical evidence supporting their use,” said Timothy J. Patrick, president and chief executive officer of Cartiva. “The initiation of this observational study represents our commitment to provide foot and ankle surgeons and their patients with meaningful clinical data to make informed treatment decisions.”

Contact

Cartiva, Inc.
Peter Pizzo, 770-754-3855
Chief Financial Officer

Back to List